1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa

SEL-212 Bested Horizon’s Drug But A New Standard Is Emerging

 
• By Mandy Jackson

Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.

On a purple background a stethoscope with yellow list with text GOUT
Selecta and Sobi already have started Phase III trials for SEL-212 • Source: Shutterstock

Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Sobi) touted a successful conclusion of the Phase IIb COMPARE clinical trial, which showed that SEL-212 performed numerically better than Horizon Therapeutics plc’s Krystexxa (pegloticase) for chronic refractory gout. However, SEL-212 did not measure up to a new emerging standard of care for this patient population, so the drug candidate’s commercial prospects may be reduced.

The COMPARE trial did not meet its primary endpoint, which compared the percentage of patients treated with SEL-212 versus the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

More from R&D

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.